NIH Funded
This program provides young talented scientists an intensive two-year research experience and training in cancer nanotechnology that is based on a close collaboration between The University of Texas MD Anderson Cancer Center and Rice University.

Future Nanotechnology Leaders
The program is geared toward scientists who aim to pursue integrated, translational research that is focused on advancing promising new nanotechnology-based diagnostics and therapeutics to improve cancer care.

Mentorship
Each fellow is co-mentored by two program faculty - one from MD Anderson Cancer Center and one from Rice University.

Program Co-Directors

**Junhgae Suh, PhD, Rice University**
Associate Professor, Associate Chair of Bioengineering and Biosciences

**Konstantin Sokolov, PhD, MD Anderson Cancer Center**
Professor of Imaging Physics
Director of the Biomedical Optics & NanoDiagnostics Lab
Adjunct Professor, Biomedical Engineering at UT Austin
Adjunct Professor, Bioengineering at Rice

**Sunil Krishnan, MD, MD Anderson Cancer Center**
John E. and Dorothy J. Harris Professor
Director, Center for Radiation Oncology Research
Professor, Radiation Oncology
Professor, Experimental Radiation Oncology

Rice University Mentors

**Department of Bioengineering**

**Gang Bao, PhD** - Nanomedicine, molecular imaging, and genome editing

**Michael Diehl, PhD** - DNA nanotechnology, super-resolution imaging, nanoscale architecture of cells, cancer biomarker detection

**Rebekah Drezeck, PhD** - Gold nanoparticle platform technologies for targeted imaging and therapy of cancer

**Isaac Hilton, PhD** - CRISPR/Cas9-based technologies, relative to epigenetic modifications, gene expression, and cellular processes

**Jordan S. Miller, PhD** - Synthetic chemistry, three-dimensional (3D) printing, microfabrication, and molecular imaging

**Amina Qutub, PhD** - Novel computational methods to study mechanisms of brain tissue regeneration and cancer

**Rebecca Richards-Kortum, PhD** - Optical imaging and spectroscopy tools to reduce the incidence and mortality of cancer

**Junhgae Suh, PhD** - Genetically encoded nanoparticles

**Jeff Tabor, PhD** - Synthetic biology

**Tomasz Tkaczyk, PhD** - Optical devices, multidimensional imaging modalities

**Omrid Veiseh, PhD** - advanced nano, micro, and macro fabrication techniques

**David Zhang, PhD** - Nucleic acid nanotechnology

**Department of Chemistry**

**Naomi Halas, PhD** - Nanoscale plasmonics, ultra-sensitive chemical sensing, active plasmonics, and biomedical and energy applications

**Lon Wilson, PhD** - Bringing carbon nanotechnology to the fields of biology and medicine

MD Anderson Cancer Center Mentors

**Imaging Physics**

**James Bankson, PhD** - Magnetic resonance imaging, spectroscopy and spectroscopic imaging

**Richard Bouchard, PhD** - Clinical photoacoustic-ultrasonic and acoustic radiation force (ARF)-based elasticity imaging technologies

**SangHyun Cho, PhD** - Modeling nanoparticle-radiation interactions and novel x-ray fluorescence imaging

**David Fuentes, PhD** - High performance human assisted computational tools for image-guided interventions

**John Hazle, PhD** - Image guided therapy, MR temperature imaging, preclinical imaging

**Konstantin Sokolov, PhD** - Applications of nanotechnology and biophotonics in early detection, diagnosis/prognosis, and treatment of cancer

**Jason Stafford, PhD** - MRI, image-guided interventions, image-guided therapy, thermal therapy

**Cancer Systems Imaging**

**Pratip Bhattacharya, PhD** - Hyperpolarization, induced polarization, and dynamic nuclear polarization

**Chun Li, PhD** - Targeted imaging probes, novel drug-delivery systems for selective delivery of diagnostic and therapeutic agents

**Steven Milward, PhD** - Imaging of apoptosis and autophagy, ovarian cancer metabolism, directed evolution of imaging agents

**Mark D. Page, PhD** - Synthesis of chemical contrast agents

**David Piwnica-Worms, MD, PhD** - Molecular imaging, signal transduction, genetically encoded reporters, bioluminescence, PET

**Clinical Program Faculty**

**Sunil Krishnan, MD** - Imaging tumors and enhancing cancer radiotherapy effectiveness with metallic nanoparticles

**Vikas Kundra, MD, PhD** - Imaging gene expression, gene therapy, and responsive therapy

**Anirban Maitra, MBBS** - Pancreatic cancer, experimental therapeutics, cancer epigenetics

**Anil K. Sood, MD** - Neuroendocrine stress hormone on ovarian cancer, development of new strategies for in vivo siRNA delivery, and novel antivascular therapeutic approaches

**Frederick F. Lang, Jr., MD, FACS, FAANS** - Surgery for deep brain tumors, gene therapy for brain tumors, primary and metastatic brain tumors.
Program Eligibility

Per program requirement, fellows “must be a citizen or a noncitizen national of the United States or have been lawfully admitted for permanent residence at the time of appointment.” Noncitizen national of the United States applies to those born or with ties to the outlying U.S. possessions of American Samoa and Swains Island.

Application

Interested candidates should send via email their applications as a single pdf file with “2018 T32 Cancer Nanotechnology Application” denoted in the Subject Line.

Application packages for this year are due by May 31st, midnight CST and should include:

I. Personal information – name, postal address, e-mail address, phone number, citizenship, graduate school name, location, and your GPA. Also specify if you are applying for a postdoctoral or predoctoral position.

II. Cover letter describing specific research interests and your preferred co-mentors (no more than 1 page)

III. CV

IV. Names of three references

V. For predoctoral candidates only, submit your Rice Graduate transcript too.

More About the Cancer Nanotech T32 Fellowship

This training program includes both multidisciplinary, hands-on coursework, seminar experiences, and multidisciplinary mentorship of translational research projects.

Shared laboratory facilities and equipment provide program fellows with an outstanding research environment that combines state-of-the-art instrumentation, facilities for animal research, and vast opportunities to be an integral part of clinical trials.

The program includes a total of 25 faculty mentors (18) and co-mentors (7) from MD Anderson Cancer Center (8 mentors and 6 co-mentors) and Rice University (10 mentors and 1 co-mentor).

More About MD Anderson & Rice University

These two institutions are home to some of the most active basic research on nanoparticles and nanotechnology in the world, as well as some of the most innovative clinical translational research in cancer.

There is a natural alignment and complementarity of interests between Rice University, which provides the technological infrastructure and intellectual leadership in bioengineering, physics and chemistry, and The MD Anderson Cancer Center, which provides a clinical base for translational research in cancer imaging and therapy.

Physically, these centers of excellence in their respective realms are located within a mile from each other.

MD Anderson Cancer Center is the largest medical institution in The University of Texas System. It is located in the 1,300-acre Texas Medical Center (TMC), the largest medical district in the world. MD Anderson’s TMC campus is 15 million gross square feet. It is consistently ranked among the nation's top two cancer hospitals in U.S. News & World Report’s "America's Best Hospitals" survey.

Currently ranked 18th in U.S News & World Report’s “Best Colleges”, Rice University is renowned for its innovative teaching and research. Rice has produced 101 Fulbright scholars, 11 Truman scholars, 24 Marshall scholars, 12 Rhodes scholars, 3 Nobel Laureates, and 2 Pulitzer Prize winners.

Postdoctoral Fellowship in Translational Cancer Nanotechnology